Acerta Pharma Bv
Clinical trials sponsored by Acerta Pharma Bv, explained in plain language.
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New targeted drug shows promise for Hard-to-Treat leukemia
Disease control CompletedThis study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had a specific high-risk genetic change (deletion 17p). Some participants had already tried other treatments, while others were newly diagnos…
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising combo tackles tough blood cancers in early trial
Disease control CompletedThis early-phase study tested a new drug combination (ACP-196 plus obinutuzumab) in 69 people with chronic lymphocytic leukemia or related blood cancers. The goal was to see if the combination was safe and could shrink tumors. Participants included both those who had prior treatm…
Phase: PHASE1 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check safety and how well the drugs work together. Partic…
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC